USRE30239E - Cell proliferation and tissue invasion inhibitor - Google Patents
Cell proliferation and tissue invasion inhibitor Download PDFInfo
- Publication number
- USRE30239E USRE30239E US05/912,861 US91286178A USRE30239E US RE30239 E USRE30239 E US RE30239E US 91286178 A US91286178 A US 91286178A US RE30239 E USRE30239 E US RE30239E
- Authority
- US
- United States
- Prior art keywords
- cells
- tissue
- inhibitor
- product
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 13
- 239000003112 inhibitor Substances 0.000 title claims abstract description 13
- 230000009545 invasion Effects 0.000 title claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 102000016611 Proteoglycans Human genes 0.000 claims abstract description 5
- 108010067787 Proteoglycans Proteins 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims abstract description 3
- 108010035532 Collagen Proteins 0.000 claims abstract description 3
- 229920001436 collagen Polymers 0.000 claims abstract description 3
- 210000001519 tissue Anatomy 0.000 claims description 33
- 230000002401 inhibitory effect Effects 0.000 claims description 24
- 210000000845 cartilage Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 230000035755 proliferation Effects 0.000 claims description 15
- 210000002808 connective tissue Anatomy 0.000 claims description 12
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 230000036770 blood supply Effects 0.000 claims description 2
- 239000000284 extract Substances 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 24
- 241000283690 Bos taurus Species 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229960000789 guanidine hydrochloride Drugs 0.000 description 6
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 6
- 210000000709 aorta Anatomy 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000003104 tissue culture media Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 210000004349 growth plate Anatomy 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- GLNADSQYFUSGOU-UHFFFAOYSA-J chembl1640 Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-UHFFFAOYSA-J 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002263 laryngeal cartilage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004269 weibel-palade body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
Definitions
- the present invention relates generally to a composition of matter having activity as an inhibitor of cell proliferation .Iadd.and an inhibitor of tissue invasion. .Iaddend.More particularly, it relates to methods of preparing such composition, and to methods of inhibiting proliferation of cells utilizing such composition.
- a substance having activity as an inhibitor of cell proliferation or, as it is sometimes referred to herein, an inhibitor of cell growth is prepared by extractive methods from tissue having a high content of collagen and/or proteoglycans, and preferably from connective tissue.
- the extract may be treated so as to concentrate the inhibiting substance.
- the resultant concentrate has utility in inhibiting proliferation of cells, and particularly in inhibiting proliferation of fibroblasts and endothelial cells.
- connective tissue is extracted with an aqueous extraction medium.
- a preferred extraction medium includes a solute which does not irreversibly denature proteins or proteoglycans.
- One such preferred extraction medium comprises a 1.0-3.0 M aqueous solution of guanidine hydrochloride.
- connective tissue examples include cartilagenous and ligamentary tissues, vascular tissues, corneal tissues, dental tissues and dermal tissues.
- the connective tissue is placed in condition for extraction by mincing, comminuting, or otherwise treating it to increase the surface area of the tissue over that in its naturally-occurring condition.
- the conditioned tissue is then exposed to the aqueous extraction medium, with or without agitation, for a period of time sufficient to result in extraction of polypeptides and proteoglycans in substantial yield, or until equilibrium conditions are attained. Extraction is desirably effected at temperatures below room temperature, and preferably at approximately 5° C.
- the aqueous extract is treated to concentrate the growth inhibiting substance contained therein. It is believed that the growth inhibiting substance of the present invention is present primarily in the fraction of the extract having a molecular weight of 50,000 or below. Accordingly, the extract may be treated so as to fractionate compounds having a molecular weight of 50,000 or less from those of higher molecular weight, by molecular sieve or ultrafiltration techniques, etc. or the like. The growth inhibiting substance of the present invention may be further concentrated by removal of water, as by lyophilization of the extract.
- the growth inhibiting substance thus obtained has a marked inhibitory effect on the rate of proliferation of endothelial cells. It also inhibits proliferation of some fibroblasts, although inhibition of growth of endothelial cells. In general, the growth inhibiting substance of the present invention is more effective against the proliferation of immature cells than of mature cells.
- the extraction medium employed in the practice of the present invention may be any aqueous extraction medium, except that the extraction medium should not irreversibly denature the proteinaceous matter extracted from the connective tissue.
- a preferred extraction medium is a 1.0-3.0 M aqueous solution of guanidine hydrochloride.
- the salt should be removed from the extract, and this may be accomplished by dialysis, in accordance with known procedures.
- the concentration of the growth inhibiting substance of the present invention in the connective tissue and in the aqueous extract is low. For example, it is necessary to extract several hundred grams of connective tissue in order to obtain a few milligrams of the lyophilized extract having a molecular weight of 50,000 or below.
- extracts were prepared from bovine connective tissues.
- Bovine connective tissues which were extracted were nasal septum cartilage, scapular epiphyseal growth plate, and dermis.
- the tissues were minced and placed in five volumes of an extraction medium comprising a 1.0 M aqueous solution of guanadine hydrochloride, the solution having a pH of 6.0.
- the mixture of tissue and extraction medium was stirred for 24 hours at 5° C.
- the resultant aqueous extract was separated from the tissue and dialyzed exhaustively against water. The dialyzed extract was then lyophilized.
- Dialyzed and lyophilized extract from scapular epiphyseal growth plate was redissolved in 4.0 M guanidine hydrochloride solution, and dialyzed through an Amicon filter membrane with a pore size which allowed compounds of molecular weight 50,000 or below to pass through the membrane. Following dialysis, the solutions on both sides of the membrane were dialyzed exhaustively against water and lyophilized.
- Bovine aortic endothelial cells were cultured from aortas collected from a local slaughter house. Fresh aortas were immediately transported to the laboratory. There, the two ends of each aorta were clamped and the branches ligated. The lumen was rinsed with about 50 ml of 0.9% NaCl. The aorta was then slightly distended with 25-50 ml of complete tissue culture medium. After about 5 minutes, the fluid was removed with a syringe and needle and 5 ml aliquots dispensed into Falcon T-25 plastic flasks. The flasks were incubated at 37° C. in a humidified 5% Co 2 -air atmosphere. The cultures generally required 8-12 days to reach confluency.
- Steer fibroblasts were isolated from the subcutaneous tissue of ears from freshly slaughtered animals. Tissues were removed aseptically and incubated in a solution of 2 mg collagenase/ml HEPES. Two hours of digestion at 37° C. was sufficient to yield 1 ⁇ 10 6 cells for planting into Falcon flasks.
- Bovine embryo fibroblasts were purchased from GIBCO Corp., Grand Island, N.Y. Second passage human foreskin fibroblasts were also obtained.
- the tissue culture medium used for all cell types was RPMI 1640, obtained from GIBCO Corp., Grand Island, N.Y., supplemented with 20% fetal calf serum which had been heated for 50 minutes at 56° C. to inactivate bovine infectious agents present in the serum. Increased buffering capacity was provided by adding 20 mM HEPES. Antibiotics were added to yield a final concentration of gentamycin, 50 ⁇ g/ml and amphotericin B, 5 ⁇ g/ml in the complete medium. The medium was made up from the commercially supplied powder as a 2X concentrate and then passed through 0.22 ⁇ pore size millipore filters for sterilization.
- the lyophilized extracts were hydrated in distilled water, sterilized by filtration, and then added to the concentrated culture medium. The filtration clarified the cloudiness seen in the aqueous solution of the extract.
- tissue extracts For biological assays of the tissue extracts, established cultures of secondary cells were subcultured in 35 ⁇ 10 mm Falcon tissue culture dishes at an initial density of 2 ⁇ 10 4 cells/ml in tissue culture medium and an additional 1 ml of medium added. The next day, the medium was removed and replaced with 2 ml of tissue culture medium containing the materials to be tested or with an equal volume of control medium. Control cell counts were done at this time.
- the cultures were refed on the third day after test materials were added.
- a 2.25% solution of disodium ethylene diamine tetra-acetic acid was then prepared in Ca-Mg free phosphate buffered saline, pH 7.4.
- the cells were then removed from the dish by digesting with a 0.25% trypsin solution.
- Cell counts of the trypsin dispersed cells were done with a hemocytometer after staining with a 1% filtered solution of tripan blue.
- Two culture dishes were counted each day for each experimental treatment. Each set of experiments was repeated at least four times. At the termination of the experiments, some cultures were fixed in 70% methanol and stained with hematoxylin.
- counts were done only at the beginning of the experiment and 3 days after the test material was added. In such experiments, three dishes were counted for each dose and the experiment was repeated three times.
- Lyophilized extracts of dermis did not inhibit growth of fetal bovine fibroblasts, although they did inhibit growth of endothelial cells as effectively as cartilage extracts. Lyophilized extracts of bovine aorta and of canine cartilage also inhibited endothelial cell growth.
- an extract was prepared from bovine cartilage utilizing an alternate extraction method.
- Bovine nasal septum cartilage was minced and placed in five volumes of an extraction medium comprising a 1.0 M aqueous solution of guanidine hydrochloride, the solution having a pH of 6.0 The mixture of tissue and extraction medium was stirred for 48 hours at 5° C.
- the resultant aqueous extract was separated from the tissue, and guanidine hydrochloride was added to the aqueous extract in an amount sufficient to raise the concentration from 1.0 M to 3.0 M.
- the resultant 3.0 M aqueous extract was subjected to pressure dialysis, using a dialysis membrane which permitted passage through it of materials having a molecular weight below about 100,000. Dialysis was continued until equilibrium was attained. About 10% of the substance extracted from the tissue passed through the dialysis membrane.
- the resultant dialysate comprising extracted substance having a molecular weight below about 100,000, was again subjected to pressure dialysis, using a membrane which permitted passage through it of materials having a molecular weight of below about 50,000.
- the resultant dialysate was collected and dialysed exhaustively against water through a membrane to deplete it of guanidine hydrochloride and other substances having a molecular weight below about 3,500.
- the dialyzed extract was lyophilized to provide a substance which also had activity as an inhibitor of cell proliferation.
- composition of matter having activity as an inhibitor of cell proliferation
- methods of preparing such a composition and methods of inhibiting cell proliferation utilizing such a composition are also been provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A composition of matter having activity as an inhibitor of cell proliferation .Iadd.and tissue invasion.Iaddend.is obtained by aqueous extraction of tissue having a high content of collagen and/or proteoglycans.
Description
The invention described herein was made in the course of work under a grant or award from the Department of Health, Education and Welfare.
The present invention relates generally to a composition of matter having activity as an inhibitor of cell proliferation .Iadd.and an inhibitor of tissue invasion. .Iaddend.More particularly, it relates to methods of preparing such composition, and to methods of inhibiting proliferation of cells utilizing such composition.
In accordance with the present invention, a substance having activity as an inhibitor of cell proliferation or, as it is sometimes referred to herein, an inhibitor of cell growth, is prepared by extractive methods from tissue having a high content of collagen and/or proteoglycans, and preferably from connective tissue. The extract may be treated so as to concentrate the inhibiting substance. The resultant concentrate has utility in inhibiting proliferation of cells, and particularly in inhibiting proliferation of fibroblasts and endothelial cells.
More particularly, in the preferred embodiment of the present invention, connective tissue is extracted with an aqueous extraction medium. A preferred extraction medium includes a solute which does not irreversibly denature proteins or proteoglycans. One such preferred extraction medium comprises a 1.0-3.0 M aqueous solution of guanidine hydrochloride.
Examples of connective tissue which may be used in the preferred embodiment of the present invention include cartilagenous and ligamentary tissues, vascular tissues, corneal tissues, dental tissues and dermal tissues. The connective tissue is placed in condition for extraction by mincing, comminuting, or otherwise treating it to increase the surface area of the tissue over that in its naturally-occurring condition. The conditioned tissue is then exposed to the aqueous extraction medium, with or without agitation, for a period of time sufficient to result in extraction of polypeptides and proteoglycans in substantial yield, or until equilibrium conditions are attained. Extraction is desirably effected at temperatures below room temperature, and preferably at approximately 5° C.
Following extraction, the aqueous extract is treated to concentrate the growth inhibiting substance contained therein. It is believed that the growth inhibiting substance of the present invention is present primarily in the fraction of the extract having a molecular weight of 50,000 or below. Accordingly, the extract may be treated so as to fractionate compounds having a molecular weight of 50,000 or less from those of higher molecular weight, by molecular sieve or ultrafiltration techniques, etc. or the like. The growth inhibiting substance of the present invention may be further concentrated by removal of water, as by lyophilization of the extract.
The growth inhibiting substance thus obtained has a marked inhibitory effect on the rate of proliferation of endothelial cells. It also inhibits proliferation of some fibroblasts, although inhibition of growth of endothelial cells. In general, the growth inhibiting substance of the present invention is more effective against the proliferation of immature cells than of mature cells.
The extraction medium employed in the practice of the present invention may be any aqueous extraction medium, except that the extraction medium should not irreversibly denature the proteinaceous matter extracted from the connective tissue. An aqueous extraction medium containing a relatively high salt content, i.e., 1.0-3.0 M, is desirably used. A preferred extraction medium is a 1.0-3.0 M aqueous solution of guanidine hydrochloride.
If a high salt aqueous extraction medium is used, the salt should be removed from the extract, and this may be accomplished by dialysis, in accordance with known procedures.
The concentration of the growth inhibiting substance of the present invention in the connective tissue and in the aqueous extract is low. For example, it is necessary to extract several hundred grams of connective tissue in order to obtain a few milligrams of the lyophilized extract having a molecular weight of 50,000 or below.
As a specific example of the preparation of the growth inhibiting substance of the present invention, extracts were prepared from bovine connective tissues. Bovine connective tissues which were extracted were nasal septum cartilage, scapular epiphyseal growth plate, and dermis. The tissues were minced and placed in five volumes of an extraction medium comprising a 1.0 M aqueous solution of guanadine hydrochloride, the solution having a pH of 6.0. The mixture of tissue and extraction medium was stirred for 24 hours at 5° C. The resultant aqueous extract was separated from the tissue and dialyzed exhaustively against water. The dialyzed extract was then lyophilized.
Dialyzed and lyophilized extract from scapular epiphyseal growth plate was redissolved in 4.0 M guanidine hydrochloride solution, and dialyzed through an Amicon filter membrane with a pore size which allowed compounds of molecular weight 50,000 or below to pass through the membrane. Following dialysis, the solutions on both sides of the membrane were dialyzed exhaustively against water and lyophilized.
There were thereby obtained lyophilized extracts of bovine cartilage and of bovine dermis, as well as lyophilized extracts from bovine cartilage which had been fractionated into an extract having a molecular weight of 50,000 or below and an extract having a molecular weight higher than 50,000. These lyophilized extracts were then used to demonstrate their activity as inhibitors of cell proliferation.
Cultures of various tissue cell types were prepared for test purposes. Bovine aortic endothelial cells were cultured from aortas collected from a local slaughter house. Fresh aortas were immediately transported to the laboratory. There, the two ends of each aorta were clamped and the branches ligated. The lumen was rinsed with about 50 ml of 0.9% NaCl. The aorta was then slightly distended with 25-50 ml of complete tissue culture medium. After about 5 minutes, the fluid was removed with a syringe and needle and 5 ml aliquots dispensed into Falcon T-25 plastic flasks. The flasks were incubated at 37° C. in a humidified 5% Co2 -air atmosphere. The cultures generally required 8-12 days to reach confluency.
Steer fibroblasts were isolated from the subcutaneous tissue of ears from freshly slaughtered animals. Tissues were removed aseptically and incubated in a solution of 2 mg collagenase/ml HEPES. Two hours of digestion at 37° C. was sufficient to yield 1×106 cells for planting into Falcon flasks.
Bovine embryo fibroblasts were purchased from GIBCO Corp., Grand Island, N.Y. Second passage human foreskin fibroblasts were also obtained.
The tissue culture medium used for all cell types was RPMI 1640, obtained from GIBCO Corp., Grand Island, N.Y., supplemented with 20% fetal calf serum which had been heated for 50 minutes at 56° C. to inactivate bovine infectious agents present in the serum. Increased buffering capacity was provided by adding 20 mM HEPES. Antibiotics were added to yield a final concentration of gentamycin, 50 μg/ml and amphotericin B, 5 μg/ml in the complete medium. The medium was made up from the commercially supplied powder as a 2X concentrate and then passed through 0.22μ pore size millipore filters for sterilization.
When tissue extracts or other materials were to be added, the lyophilized extracts were hydrated in distilled water, sterilized by filtration, and then added to the concentrated culture medium. The filtration clarified the cloudiness seen in the aqueous solution of the extract.
For biological assays of the tissue extracts, established cultures of secondary cells were subcultured in 35×10 mm Falcon tissue culture dishes at an initial density of 2×104 cells/ml in tissue culture medium and an additional 1 ml of medium added. The next day, the medium was removed and replaced with 2 ml of tissue culture medium containing the materials to be tested or with an equal volume of control medium. Control cell counts were done at this time.
The cultures were refed on the third day after test materials were added. A 2.25% solution of disodium ethylene diamine tetra-acetic acid was then prepared in Ca-Mg free phosphate buffered saline, pH 7.4. The cells were then removed from the dish by digesting with a 0.25% trypsin solution. Cell counts of the trypsin dispersed cells were done with a hemocytometer after staining with a 1% filtered solution of tripan blue. Two culture dishes were counted each day for each experimental treatment. Each set of experiments was repeated at least four times. At the termination of the experiments, some cultures were fixed in 70% methanol and stained with hematoxylin. For dose-response curve studies of cartilage-derived materials, counts were done only at the beginning of the experiment and 3 days after the test material was added. In such experiments, three dishes were counted for each dose and the experiment was repeated three times.
Since identification of endothelial cells depends in large part on the Weibel-Palade bodies, electron microscopy was done on these cultured cells and these organelles were found as expected. For this, the culture dishes were washed with 0.9% NaCl. The cells were then scraped off the culture dish with a rubber spatula, fixed in 2.5% cacodylate buffered .[.gluteraldehyde.]. .Iadd.glutaraldehyde.Iaddend., washed overnight in buffer, stained en bloc in uranyl acetate, dehydrated and embedded in Epon 812. Sections were mounted on copper grids, stained with lead citrate and studied in an electron microscope.
The effects of the lyophilized extract of bovine cartilages on the growth of endothelial cells were determined. 40,000 endothelial cells in 2 ml of culture medium were initially dispensed into 35 mm Petri dishes. The following day the extract to be tested was injected into the dish, three dishes for each extract. Three control dishes were also provided, which were refed only with culture medium the day after culturing was begun.
Three days after injection of the respective lyophilized extracts, cell counts were done on each dish. In the case of the control dishes, the original population of 40,000 cells had increased to 700,000. Table I shows the cell counts of the dishes containing lyophilized cartilage extract at three different concentrations of lyophilized extract.
TABLE I ______________________________________ EFFECT OF CARTILAGE EXTRACTION ENDOTHELIAL CELL GROWTH Dose, Cells/dish ______________________________________ micrograms lyophilized extract per ml. of culture medium 500 52,000 100 285,000 20 510,000 0 700,000 ______________________________________
It will be seen from Table I that at a dosage of 500 micrograms of lyophilized extract per milliliter of culture medium, proliferation of endothelial cells was substantially inhibited, the cell count increasing only to 52,000 from the original count of 40,000. At lower dosages, inhibition was less complete, but in each case the cell count was substantially less than the 700,000 cell count of the control after 3 days.
Similar testing was done utilizing the fraction of lyophilized cartilage extract having a molecular weight greater than 50,000. There was no observed inhibition of proliferation of endothelial cells using this fraction, the cell count at a dosage level of 500 micrograms/milliliter being 710,000 after three days, not substantially different from the cell count of 700,000 in the control.
However, the fraction of lyophilized cartilage extract having a molecular weight of 50,000 and below was substantially more potent as a growth inhibitor than the lyophilized extract which was the subject of Table I. Table II shows the results of this test, which was carried out in the same manner as testing of the unfractionated extract.
TABLE II ______________________________________ EFFECT OF CARTILAGE EXTRACT HAVING A MOLECULAR WEIGHT OF 50,000 AND BELOW ON ENDOTHELIAL CELL GROWTH Dose Cells/dish ______________________________________ micrograms lyophilized extract per ml. of culture medium 500 22,000 100 65,000 20 260,000 5 300,000 0 700,000 ______________________________________
It will be seen from Table II that the fraction of lyopholized extract having a molecular weight of 50,000 or below was effective at inhibiting proliferation of endothelial cells at dosages as low as 5 micrograms per milliliter.
The tests of which the results are reported in Tables I and II were repeated three times, and gave virtually identical results.
The same lyophilized extracts of bovine cartilage used in the tests of which the results are shown in Tables I and II were evaluated for activity in inhibiting proliferation of mature steer fibroblasts in the same culture medium. There was no significant growth inhibition, now was there significant growth inhibition of steer fibroblasts by lyophilized extracts of dermis. However, lyophilized extract from bovine cartilage was found to inhibit proliferation of fetal bovine fibroblasts. The inhibitory effect of lyophilized extract from bovine cartilage on fetal bovine fibroblasts was less marked than the inhibitory effect on bovine endothelial cells. There was also growth inhibition by extracts from bovine cartilage on infant human foreskin fibroblasts, but again the degree of inhibition was less marked than in the case of endothelial cells.
Lyophilized extracts of dermis did not inhibit growth of fetal bovine fibroblasts, although they did inhibit growth of endothelial cells as effectively as cartilage extracts. Lyophilized extracts of bovine aorta and of canine cartilage also inhibited endothelial cell growth.
The inhibitory effect of extracts from connective tissue on cell proliferation is believed to provide an explanation as to why some such tissues are relatively resistant to invasion by either neoplasms or inflammatory processes. It has been observed for many years that poorly vascularized or avascular tissues such as cartilage are relatively resistant to invasion. Clinicians and pathologist have long known, for example, that most forms of cancers of the respiratory passages often encase, but seldom invade, bronchial or laryngeal cartilages. More recently, investigation of the resistance of certain tissues to invasion by explantation on to the chick chorioallantoic membrane showed that tissues which normally have a blood supply are rapidly invaded by vascularized mesenchyme originating from the chick embryo. On the other hand, post-natal hyaline cartilage, which is virtually devoid of blood vessels, was substantially impenetrable under the same conditions. American Journal of Pathology, Volume 73, No. 3 Pages 765-772, December 1973. Although applicants do not intend to be bound by theory, nor to restrict the scope of their invention by theory, it is believed that the presence of the cell proliferation inhibiting substance of the present invention at relatively high concentrations in poorly vascularized or avascular tissues such as cartilage and blood vessels is responsible for the resistance of such tissues to invasion.
As a further specific example of the preparation of the growth inhibiting substance of the present invention, an extract was prepared from bovine cartilage utilizing an alternate extraction method. Bovine nasal septum cartilage was minced and placed in five volumes of an extraction medium comprising a 1.0 M aqueous solution of guanidine hydrochloride, the solution having a pH of 6.0 The mixture of tissue and extraction medium was stirred for 48 hours at 5° C.
The resultant aqueous extract was separated from the tissue, and guanidine hydrochloride was added to the aqueous extract in an amount sufficient to raise the concentration from 1.0 M to 3.0 M. The resultant 3.0 M aqueous extract was subjected to pressure dialysis, using a dialysis membrane which permitted passage through it of materials having a molecular weight below about 100,000. Dialysis was continued until equilibrium was attained. About 10% of the substance extracted from the tissue passed through the dialysis membrane.
The resultant dialysate comprising extracted substance having a molecular weight below about 100,000, was again subjected to pressure dialysis, using a membrane which permitted passage through it of materials having a molecular weight of below about 50,000. The resultant dialysate was collected and dialysed exhaustively against water through a membrane to deplete it of guanidine hydrochloride and other substances having a molecular weight below about 3,500. The dialyzed extract was lyophilized to provide a substance which also had activity as an inhibitor of cell proliferation.
Thus, there has been provided a composition of matter having activity as an inhibitor of cell proliferation, and there has also been provided methods of preparing such a composition and methods of inhibiting cell proliferation utilizing such a composition.
Various of the features of the present invention are set forth in the following claims.
Claims (10)
1. The method of preparing a composition of matter having activity as an inhibitor of cell proliferation .Iadd.and tissue invasion .Iaddend.comprising the steps of providing connective tissue having a high content of collagen or proteoglycans in condition for extraction, extracting said inhibitor from said tissue with an aqueous extraction medium which includes a solute which does not irreversibly denature the proteinaceous matter to be extracted, separating the resultant aqueous extract from the tissue, recovering from the aqueous extract substances having a molecular weight below about 50,000, treating the fraction of aqueous extract having a molecular weight below about 50,000 to remove salts therefrom, and dehydrating the resultant material.
2. The method of claim 1 wherein the connective tissue comprises tissue normally devoid of an intimate capillary blood supply.
3. The method of claim 2 wherein the tissue comprises cartilage.
4. The method of claim 2 wherein the tissue comprises blood vessels.
5. A composition of matter having activity as an inhibitor of cell proliferation .Iadd.and tissue invasion .Iaddend.comprising the product of the method of claim 1.
6. A composition of matter having activity as an inhibitor of cell proliferation comprising the product of the method of claim 2.
7. A method of inhibiting proliferation of cells comprising treating the cells with the product of claim 1.
8. A method of inhibiting proliferation of cells comprising treating the cells with the product of claim 2.
9. A method of inhibiting proliferation of cells comprising treating the cells with the product of claim 3.
10. A method of inhibiting proliferation of cells comprising treating the cells with the product of claim 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/912,861 USRE30239E (en) | 1975-11-10 | 1978-06-05 | Cell proliferation and tissue invasion inhibitor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/630,275 US4042457A (en) | 1975-11-10 | 1975-11-10 | Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor |
| US05/912,861 USRE30239E (en) | 1975-11-10 | 1978-06-05 | Cell proliferation and tissue invasion inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/630,275 Reissue US4042457A (en) | 1975-11-10 | 1975-11-10 | Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE30239E true USRE30239E (en) | 1980-03-25 |
Family
ID=27091120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/912,861 Expired - Lifetime USRE30239E (en) | 1975-11-10 | 1978-06-05 | Cell proliferation and tissue invasion inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | USRE30239E (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981003031A1 (en) * | 1980-04-22 | 1981-10-29 | Rush Presbyterian St Luke | Anti-invasion factor containing cultures |
| US4486416A (en) | 1981-03-02 | 1984-12-04 | Soll David B | Protection of human and animal cells subject to exposure to trauma |
| US4534967A (en) | 1982-08-03 | 1985-08-13 | Boston Biomedical Research Institute | Cell proliferation inhibitor and method of preparation |
| US4770877A (en) | 1982-08-03 | 1988-09-13 | Boston Biomedical Research Institute | Isolation of a high molecular weight aortic endothelial cell growth inhibitor |
| EP0257312A3 (en) * | 1986-07-30 | 1989-10-25 | Hoechst Aktiengesellschaft | A new cartilage-derived leukocyte elastase-inhibitor |
| US4996159A (en) * | 1985-02-26 | 1991-02-26 | The Johns Hopkins University | Neovascularization inhibitors and methods for their production and use |
| US5036056A (en) * | 1987-07-08 | 1991-07-30 | Martin Kludas | Methods for treating damaged corneal, uterine, or cartilage tissue |
| US5055298A (en) * | 1987-12-01 | 1991-10-08 | Chemisches Laboratorium Dr. Kurt Richter Gmbh | Cosmetic composition comprising an extracellular connective tissue matrix |
| US5242692A (en) * | 1990-07-10 | 1993-09-07 | Bar Ilan University | Anti-metastatic factor |
| WO1994000484A1 (en) * | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
| US6451326B2 (en) | 1996-05-02 | 2002-09-17 | Burt D. Ensley | Cosmetic compositions |
| US6506411B2 (en) | 1993-07-19 | 2003-01-14 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
-
1978
- 1978-06-05 US US05/912,861 patent/USRE30239E/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| Willmer-Cells and Tissues in Culture, vol. 1 (1965), pp. 44 and 573. * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0038719A3 (en) * | 1980-04-22 | 1982-08-04 | Rush-Presbyterian-St.Luke's Medical Center | Method for culturing chondrocytes to produce cultures and method for extracting anti-invasion factor therefrom |
| US4356261A (en) | 1980-04-22 | 1982-10-26 | Rush-Presbyterian-St. Luke's Medical Center | Anti-invasion factor containing cultures |
| WO1981003031A1 (en) * | 1980-04-22 | 1981-10-29 | Rush Presbyterian St Luke | Anti-invasion factor containing cultures |
| US4486416A (en) | 1981-03-02 | 1984-12-04 | Soll David B | Protection of human and animal cells subject to exposure to trauma |
| US4534967A (en) | 1982-08-03 | 1985-08-13 | Boston Biomedical Research Institute | Cell proliferation inhibitor and method of preparation |
| US4770877A (en) | 1982-08-03 | 1988-09-13 | Boston Biomedical Research Institute | Isolation of a high molecular weight aortic endothelial cell growth inhibitor |
| US4996159A (en) * | 1985-02-26 | 1991-02-26 | The Johns Hopkins University | Neovascularization inhibitors and methods for their production and use |
| EP0257312A3 (en) * | 1986-07-30 | 1989-10-25 | Hoechst Aktiengesellschaft | A new cartilage-derived leukocyte elastase-inhibitor |
| US5036056A (en) * | 1987-07-08 | 1991-07-30 | Martin Kludas | Methods for treating damaged corneal, uterine, or cartilage tissue |
| US5055298A (en) * | 1987-12-01 | 1991-10-08 | Chemisches Laboratorium Dr. Kurt Richter Gmbh | Cosmetic composition comprising an extracellular connective tissue matrix |
| US5242692A (en) * | 1990-07-10 | 1993-09-07 | Bar Ilan University | Anti-metastatic factor |
| WO1994000484A1 (en) * | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
| US6506411B2 (en) | 1993-07-19 | 2003-01-14 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
| US6451326B2 (en) | 1996-05-02 | 2002-09-17 | Burt D. Ensley | Cosmetic compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4042457A (en) | Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor | |
| Kohler et al. | Platelets as a source of fibroblast growth-promoting activity | |
| Ronchi et al. | Stimulation of carrot somatic embryogenesis by proline and serine | |
| USRE30239E (en) | Cell proliferation and tissue invasion inhibitor | |
| Glaser et al. | Retinal pigment epithelial cells release an inhibitor of neovascularization | |
| DE3686927T2 (en) | NEOVASCULARIZATION INHIBITORS AND THEIR PRODUCTION. | |
| Chang | Effects of heterologous sera on fertilized rabbit ova | |
| SE451850B (en) | SET TO MAKE A GLYCOPROTEIN WITH KNOWN ABILITY TO STIMULATE EDUCATION AND DIFFERENTIZATION OF HUMAN GRANULOCYTES | |
| EP0140134A2 (en) | Process for the preparation of a biologically active extract | |
| Ribeiro et al. | Platelet antiaggregating activity in the salivary secretion of the blood sucking bug Rhodnius prolixus | |
| CN110812318B (en) | Method for preparing optimized fibroblast extract for cosmetic raw material | |
| Katsumoto et al. | Stimulation of DNA synthesis in hepatocytes by Kupffer cells after partial hepatectomy | |
| DE2645993C2 (en) | ||
| CN107427535A (en) | Blood clot through modification | |
| KR20180052946A (en) | Serum-free medium for animal cell culture | |
| Fukuda et al. | A tissue-culture of nerve cells from adult mammalian ganglia and some electrophysiological properties of the nerve cells in vitro | |
| Hagiwara et al. | Prevention of peritoneal metastasis of cancer with dextran sulfate—An experimental study in mice | |
| CA1073383A (en) | Cell proliferation and tissue invasion inhibitor | |
| Estin et al. | Primary glial cells and brain fibroblasts: interactions in culture | |
| EP0517789B1 (en) | Inhibitor of proliferation of endothelial cells | |
| Watanabe | CHANGES IN THE CAPACITY FOR CLONAL GROWTH AND DIFFERENTIATION IN VITRO OF THE VERTEBRAL CARTILAGE CELLS WITH EMBRYONIC DEVELOPMENT II. VITALIZING EFFECT OF CONDITIONED MEDIUM ON THE CELLS OF YOUNGER EMBRYOS | |
| Demetriou et al. | Effect of sera obtained from normal and partially hepatectomized rats and patients on the growth of cells in tissue culture | |
| Vanden Berghe et al. | Specific stimulation of human endothelial cells by Triticum vulgare extract and its biologically active fraction | |
| AU2018100588A4 (en) | Cell culture mediums containing aqueous extract derived from herbal medicines | |
| Thibaudeau et al. | Inhibition of neural crest cell differentiation by embryo ectodermal extract |